CymaBay Therapeutics reported positive top-line results from the ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy […]
Immunic Therapeutics reported positive top-line data from the phase 2 EMPhASIS trial evaluating IMU-838 versus placebo in patients with relapsing […]
Indiana University School of Medicine announced today a strategic research agreement with Eli Lilly and Company designed to, in the […]
Francesco Boin, MD, a nationally recognized rheumatology expert, has been appointed the director of the division of Rheumatology and director […]
Celltrion Healthcare is partnering with the University of Oxford and University Hospitals Birmingham to study the use of CT-P13 (biosimilar […]
A Georgia State University professor received a five-year, $1.95 million federal grant to study the causes of autoimmunity in the […]
Ocugen announced the decision to discontinue the Phase 3 trial of OCU300 for ocular Graft vs. Host Disease (oGVHD). The decision […]
SOBI announced that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients […]
Akari Therapeutics announced that it achieved the primary and secondary endpoints in a phase 2 study evaluating nomacopan for the […]
The Hospital for Special Surgery (HSS) in New York City has discovered a molecule in the lymphatic system that could […]
